<DOC>
	<DOC>NCT02775916</DOC>
	<brief_summary>This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173, a selective PI3K Delta inhibitor, for 12 weeks, in patients with primary Sjögren's syndrome. Data from this study will provide basis for further development of the compound for the treatment of primary Sjögren's syndrome.</brief_summary>
	<brief_title>Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome</brief_title>
	<detailed_description>This study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173, a selective PI3K delta inhibitor, for 12 weeks, in patients with primary Sjögren's syndrome. Data from this study will provide the basis for further development of the compound for the treatment of primary Sjögren's syndrome.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>Diagnosis of primary Sjögren's syndrome (pSS) ESSDAI score ≥ 6; Secondary Sjögren's syndrome Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>